united states: fda approves first anti-diarrheal drug for hiv/aids patients

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update UNITED STATES: FDA Approves First Anti-Diarrheal Drug for HIV/AIDS Patients Staff Writer
January 2, 2013

FDA News Release (12.31.12) Aids Weekly Plus On December 31, the US Food and Drug Administration approved Fulyzaq (Crofelemer) to treat diarrhea symptoms in HIV/AIDS patients currently on antiretroviral therapy (ART). Many ART patients either change or discontinue their therapies because of the resultant diarrhea. Fulyzaq is intended for HIV/AIDS patients whose diarrhea is not caused by infection from a virus, bacteria, or parasite. Derived from the red sap of the Croton lechleri plant, Fulyzaq is only the second botanical prescription drug approved by the FDA—a botanical drug can be a complex mixture derived from one or more plant materials of varying degrees of purity. Currently, there are no other FDA-approved therapies for HIV-associated diarrhea, according to Julie Beitz, MD, director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims PENNSYLVANIA: Area Residents Screened for Hepatitis C on Sunday COLORADO: Peer to Peer: Teens Work to Educate Peers on Pregnancy, STDs at CCHS OREGON: Portland Barefoot 3 x 3 Benefit Tournament to Draw Hundreds to Northeast Portland TEXAS: Temple - Wellness and Sexual Health Classes Helping Kids to Abstain CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students EUROPE: EU Issues Stringent Sharps Regulations CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students Too many patients, too little time After a decade, global AIDS program looks ahead General Secretariat of the League of Arab States and UNAIDS to work toward an accelerated HIV response in the Arab Region HarborPath Receives $250,000 Elton John AIDS Foundation Grant to Support Program Expansion OHIO: Cleveland LGBT Community Center Offers Free Support Groups and HIV, STD Testing: The Frugal Patient CALIFORNIA: Local Church Sends HIV/AIDS Care Packs to Swaziland ITALY: HIV Is No Barrier to Successful Liver Transplant for Cancer Treatment
Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles. Information in this article was accurate in January 2, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.